CLINICAL OPERATIONS & OUTSOURCING


The world’s changing climate is already presenting wide-ranging public health impacts, and the pharma industry is positioned to respond to  and, natrally, profit from  evolving disease burdens and emerging public health crises. The Covid-19 pandemic has highlighted


the vale of the indstrys wor, from the incredible speed of mA vaccine technology to the gamechanging potential of the oral antivirals that are now approaching regulatory clearance. But some companies have been criticised for their monetisation of the coronavirus and, as human rights group Amnesty International has arged, ptting profit before access to health for all by refsing to share intellectal property. That ind of comment from Amnesty is


completely nhelpfl in the global conversation, choichet conters. o cant ship drgs that reire cold chain


to the middle of a place that has no trained doctors, no hospitals and no refrigeration. Theres been a tremendos amont of wor on cross-licensing and production issues to ramp p the spply.


Social impact and access to medicines choichet adds that social impact, and


access to medicines in particular, has been a consistent theme at the Biopharma stainability ondtable. The conversation has really grown in focs


to the social impact isses, lie access to medicines and eitable participation in clinical trials, and so on. o thats where we see the biggest valeadd from the indstry, says choichet


IA has been woring on both climate


change mitigation issues – through the CHEM  green manfactring project, for eample – and climate-related response plans with the Innovative edicines Initiative. eid highlights the bola virs epidemic in


western Africa as an eample of the vale of indstry collaboration in tacling emerging health threats. nder the Innovative edicines Initiative, we had a callot for projects on bola, and it reslted in two new lifesaving vaccines, for new diagnostics, and new identification and compliance tools, she says.


14 | Outsourcing In Clinical Trials


Hopes and expectations from COP26 With COP26 only days away and poised as a critical moment to avert climate disaster, the pharma industry is ramping up its commitments and its messaging on targeting netero, a ey component of this years tals, both for contries and bsinesses. mmit partner  has annonced a raft of


renewable energy commitments, including a year ower rchase Agreement involving electricity spply from two new wind trbines and a  solar farm for its Irvine manfactring site in cotland, which crrently acconts for  of   emissions from manfactring. The company is also taing fresh action on


metereddose asthma inhalers, the se of which represents a stnning 5 of s total carbon emissions. A loweremission propellant crrently in preclinical testing cold, if sccessfl, ct greenhose gas emissions from inhalers by ,  said in a late eptember press release dring ew or limate ee. n the other side of the coin, what are pharma companies hoping to see come ot of  eid describes global climate health eity as a priority item, as well as moving forward on sciencebased targets and promoting a holistic, global perspective on solving climate challenges. ontai emphasises the need for consistency and clarity on reglatory reirements related to climate change and the environment to avoid the patchwor of regional reirements that crrently eists. hether a standard lie the Tas orce on limaterelated inancial Disclosures (TCFD) will become truly global is a ey estion, becase companies need to now if a reirement is going to become a eystone, or merely another thread in a confsing tapestry. reater clarity is certainly something


that pharma wold be looing for, she says. And, certainty, in terms of whats reired, becase global companies, not jst for climate, have this consistent isse of one region wants this and the other wants that in terms of reglators and policymaers, contines ontai. That creates a brden that is not condcive


to necessarily becoming better at what you do. It jst creates more breacracy.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72